1 – 10 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes
(
- Contribution to journal › Article
- 2019
-
Mark
Glucagon-like peptide-1 receptor agonists for type 2 diabetes : A rational drug development
(
- Contribution to journal › Article
-
Mark
Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
(
- Contribution to journal › Article
-
Mark
DPP-4 inhibition and the path to clinical proof
(
- Contribution to journal › Article
- 2018
-
Mark
Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects
(
- Contribution to journal › Article
-
Mark
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
(
- Contribution to journal › Article
-
Mark
DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes : A randomized, placebo-controlled study
(
- Contribution to journal › Article
- 2017
-
Mark
Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus : Results over 52 weeks
(
- Contribution to journal › Article